Floatz logo

PEGIPANERMIN

Neurocognitive Disorders

Inmune Bio, Inc.protein_peptidePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Neurocognitive Disorders cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Eli Lilly and Company
Phase 3B
Donanemab
Eli Lilly and Company
Phase 3B
NA 831
Biomed Industries, Inc.
Phase 2B
Rotigotine
I.R.C.C.S. Fondazione Santa Lucia
Phase 2B
Tolcapone
Sheppard Pratt Health System
Phase 2CCC

View all 9 →

Same molecule, other indications

PEGIPANERMIN is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
dementiaDormant
CCC
Indicative ·
48 / 100
View asset →
brain disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →